期刊文献+

宫颈病变中心体异常扩增与高危人乳头状瘤病毒感染相关性 被引量:8

Relationship of abnormal centrosome amplification in cervical lesions with its high-risk human papillomavirus infection
原文传递
导出
摘要 目的探讨宫颈病变中中心体异常扩增与高危人乳头状瘤病毒(high-risk human papillomavirus,HR-HPV)感染的关系。方法对46例宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)(CIN组)、43例宫颈鳞状细胞癌患者(宫颈鳞癌组)及20例正常宫颈组织者(对照组)进行宫颈脱落细胞的HR-HPV基因型检测,另采用间接免疫荧光染色技术检测中心体。结果对照组、CIN组及宫颈鳞癌组HR-HPV感染阳性率依次增高,分别为5.00%、78.26%、93.02%,组间比较差异均有统计学意义(P<0.05);CIN组与宫颈鳞癌组细胞中心体异常细胞率分别为(1.76±1.74)%、(4.46±2.08)%,2组比较差异有统计学意义(P<0.05);双变量相关分析显示宫颈病变中,中心体异常细胞率和HR-HPV感染呈正相关(r=0.452,P=0.000)。结论宫颈鳞癌发生、发展过程中,中心体异常扩增与HR-HPV感染密切相关;HR-HPV感染可能通过引起中心体的异常扩增诱发宫颈癌变。 Objective To explore the relationship of abnormal centrosome amplification with high-risk human papillomavirus(HR-HPV)infection in cervical lesions.Methods HPV-DNA in cervical exfoliated cells was detected in46 cases of cervical intraepithelial neoplasia(CIN)(CIN group),43 cases of cervical squamous cell carcinoma(cervical carcinoma group)and 20 cases of normal cervical tissue(control group).And the centrosome was detected by indirect immunofluorescence.Results The positive rates of HR-HPV infection were 5.00%,78.26% and 93.02% in control group,CIN group and cervical carcinoma group,showing significant differences among groups(P〈0.05).The rate of abnormal centrosome was(1.76±1.74)% in CIN group,significantly different from that in cervical carcinoma group((4.46±2.08)%)(P〈0.05).Bivariate correlation analysis showed that the rate of abnormal centrosome was positively correlated with HR-HPV infection in cervical lesions(r=0.452,P=0.000).Conclusion In the development and progression of cervical squamous cell carcinoma,abnormal centrosome amplification is closely correlated with HR-HPV infections.HR-HPV infection may lead to cervical cancer by inducing centrosome amplification.
出处 《中华实用诊断与治疗杂志》 2015年第3期247-249,共3页 Journal of Chinese Practical Diagnosis and Therapy
关键词 子宫颈鳞状细胞癌 宫颈上皮内瘤变 中心体 高危型人乳头瘤病毒 Cervical squamous cell carcinoma cervical intraepithelial neoplasia centrosome high-risk human papillomavirus
  • 相关文献

参考文献3

二级参考文献33

  • 1刁兆光,郭涛,廖东明.医院后勤工作中事故的预防[J].中国医院建筑与装备,2002,3(3):34-35. 被引量:2
  • 2陶萍萍,卞美璐,李敏,刘军.HPV多重感染与宫颈病变关系探讨[J].中国妇产科临床杂志,2006,7(2):94-96. 被引量:112
  • 3刘艳杰,乔玉环,郭瑞霞.24例年轻女性宫颈癌的临床分析[J].实用诊断与治疗杂志,2007,21(2):146-147. 被引量:10
  • 4Doorbar J. Molecular biology of human papilomavirus infection and cervical cancer[J]. Clin Sci(Lond), 2006,110(5) : 525-541.
  • 5Pontus N, Walter R, Sven T. Human papillomavirus and papanicolaou tests to screen for cervical cancer[J]. N Engl J Med,2007,357(16) :1589- 1597.
  • 6Park J Y, Kim D Y, Kim J H, et al. Human papillomavirus test after conization in predicting residual disease in subsequent hysterectomy specimens[J]. Obstet Gynecol, 2009,114, ( 1 ) : 87- 92.
  • 7Caraway N P, Khanna A, Dawlett M, et al. Gain of 3q26 region in cervicovaginal liquid based pap preparations is associated with squamous intraepithelial lesions and squamous intraepithelial carcinoma[J]. Gynecol Oncol,2008,110(1):37-42.
  • 8Alameda F, Espinet B, Corzo C, et al. 3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence progression indicator in low-grade squamous intraepithelial lesion cases[J]. Hum Pathol, 2009,40(10) : 1474-1478.
  • 9Heselmeyer-Haddad K, Sommerfeld K, White N M, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer[J]. Am J Pathol,2005,166(4) :1229- 1238.
  • 10Jiang J, Wei L H, Li Y L, et al. Detection of TERC amplification in cervical epithelial cells for the diagnosis of high- grade cervical lesions and invasive cancer: a multicenter study in China[J]. J Mol Diagn,2010,12(6):808 -817.

共引文献31

同被引文献81

  • 1赵健,林军,林静.p16在HSIL与宫颈炎和宫颈癌病灶中的表达及与不同HPV高危分型相关性研究[J].中国预防医学杂志,2020(6):666-670. 被引量:6
  • 2章文华主编.子宫颈病变的诊断要点[M].北京:人民卫生出版社,2006:100-107.
  • 3Scaria V, Hariharan M, Brahmachari SK, et al. MicroRNA: an emerging therapeutie[J]. Chem Med Chem, 2007, 2 (6) : 789- 792.
  • 4Yuan C, et al. High-risk human papillomavirusreduces the expression of microRNA 218 in women with cervical intraepithelial neoplasia[J]. J Int Med Res, 2010,38(5) : 1730- 1736.
  • 5Jung HM, Phillips BL, Chan EK. MiR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3zeta[J]. Mol Cancer,2014, 13:80.
  • 6Tang S, Tao M, Mccoy JJ, et al. The E7 oncoprotein is translated from spliced E6 I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell fines via translation reinitiation[J]. Virol, 2006,80 (9) : 4249- 4263.
  • 7Liu W, Gao G, Hu X, et al. Activation of miR-9 by human papillomavirus in cervical cancer [ J 1. Oncotarget, 2014,5 ( 22 ), 11620-11630.
  • 8Yamamoto N, Kinoshita T, Nohata N, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamouscell carcinoma[J]. Int J Oncol, 2013,42(5):1523- 1532.
  • 9Yao T, Lin Z. MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20[J]. Biochim Biophys Acta, 2012,1822(2) : 248-260.
  • 10Duensing S, Lee LY, Duensing A, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomie instability by uncoupling centrosome duplication {tom the cell division cycle[J]. Proe Nail Acad Sci USA,2000,97(18) : 10002-10007.

引证文献8

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部